Q-omics provides the consensus-scored NAMPTP1 profile across patient tissues and cancer cell-line models. NAMPTP1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, NAMPTP1 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, NAMPTP1 RNA expression shows 18,240 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, BRCA, and GBM as cancer lineages where NAMPTP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAMPTP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAMPTP1 survival associations across molecular data types. NAMPTP1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAMPTP1 RNA expression–survival associations across cancer types. High NAMPTP1 expression shows unfavorable associations in CESC, LGG and HNSC, but favorable associations in SKCM, UCS and MESO. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SKCM as the clearest survival context for NAMPTP1 RNA expression.
This table summarizes NAMPTP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for NAMPTP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAMPTP1 shows lower tumor expression in BRCA and higher tumor expression in KIRC and COAD. The BRCA box plot shows higher NAMPTP1 RNA expression in normal versus tumor tissue (log2 FC = −1.109, t-test p = .004).
This table shows molecular features associated with NAMPTP1 in patient tissues and cancer cell lines. In patient samples, NAMPTP1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NAMPTP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST.
